Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART

• Published in: The Brazilian journal of infectious diseases Vol. 14; no. 2; pp. 158 - 166
• Main Authors: Cahn, P., Leite, O., Rosales, A., Cabello, R., Alvarez, C.A., Seas, C., Carcamo, C., Cure-Bolt, N., L’Italien, G.p., Mantilla, P., Deibis, L., Zala, C., Suffert, T.
• Format: Journal Article
• Language: English
• Published: Brazil Elsevier Editora Ltda 01.03.2010; Contexto; Elsevier
• Subjects: Adult; Anti-HIV Agents - adverse effects; Antiretroviral Therapy, Highly Active - adverse effects; Cardiovascular diseases; Cardiovascular Diseases - chemically induced; cardiovascular risk factors; Cohort Studies; Complications and side effects; Diabetes Mellitus, Type 2 - chemically induced; Drug therapy; dyslipidemia; Dyslipidemias - chemically induced; Female; HAART; Highly active antiretroviral therapy; HIV; HIV (Viruses); HIV Infections - blood; HIV Infections - complications; HIV Infections - drug therapy; Humans; Latin America; Male; Metabolic Diseases - chemically induced; metabolic parameters; metabolic syndrome; Metabolic Syndrome - chemically induced; Middle Aged; Patient outcomes; Risk Factors; Latin America; metabolic syndrome; cardiovascular risk factors; HIV; metabolic parameters; dyslipidemia; HAART
• ISSN: 1413-8670; 1678-4391
• DOI: 10.1016/S1413-8670(10)70030-1

Determine the prevalence of metabolic abnormalities (MA) and estimate the 10-year risk for cardiovascular disease (CVD) among Latin American HIV-infected patients receiving highly active anti-retroviral therapy (HAART). A cohort study to evaluate MA and treatment practices to reduce CVD has been conducted in seven Latin American countries. Adult HIV-infected patients with at least one month of HAART were enrolled. Baseline data are presented in this analysis. A total of 4,010 patients were enrolled. Mean age (SD) was 41.9 (10) years; median duration of HAART was 35 (IQR: 10-51) months, 44% received protease inhibitors. The prevalence of dyslipidemia and metabolic syndrome was 80.2% and 20.2%, respectively. The overall 10-year risk of CVD, as measured by the Framingham risk score (FRF), was 10.4 (24.7). Longer exposure to HAART was documented in patients with dyslipidemia, metabolic syndrome and type 2 diabetes mellitus. The FRF score increased with duration of HAART. Male patients had more dyslipidemia, high blood pressure, smoking habit and higher 10-year CVD than females. Traditional risk factors for CVD are prevalent in this setting leading to intermediate 10-year risk of CVD. Modification of these risk factors through education and intervention programs are needed to reduce CVD.